Agios Pharmaceuticals, Inc. AGIO 深 沪
交易中 10-06 10:35:08 美东时间
31.01
-0.240
-0.77%
华盛通- 最 高35.375
- 今 开31.49
- 成交量 10.10万股
- 最 低 30.78
- 昨 收 31.25
- 总市值 169.90万
- 52周最高 46.00
- 市盈率 静 --
- 换手率 184.42%
- 52周最低 22.24
- 委 比 81.82%
- 总股本 5.48万
- 历史最高 138.85
- 量 比 0.82
- 振 幅 14.70%
- 历史最低 1.10
- 每 手 1
- 风险率 5.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
Agios Pharmaceuticals stops tebapivat development in sickle cell disease after Phase 2 study fails to prove meaningful differentiation.
07-21 23:44
US Stocks Mixed; Cleveland-Cliffs Shares Fall After Q1 Results
US stocks mixed, energy shares climb. Cleveland-Cliffs falls 6% after reporting Q1 results. Enveric Biosciences, Fitness Champs, Clearmind Medicine surge.
04-20 22:08
Earnings Summary: Agios Pharmaceuticals Q4
The earnings results for Agios Pharmaceuticals (NASDAQ:AGIO) for Q4 were made p...
02-12 19:36
Earnings Scheduled For February 12, 2026
Companies Reporting Before The Bell • Ambev (NYSE:ABEV) is estimated to report ...
02-12 19:11
FDA Approves Agios Drug For Thalassemia-Associated Anemia
FDA approves Agios' Aqvesme for anemia in alpha and beta thalassemia, backed by Phase 3 data and a REMS safety program.
2025-12-24 20:31
Crude Oil Falls Over 2%; Lowe's Shares Gain After Q3 Results
U.S. stocks traded mixed midway through trading, with the Dow Jones index falli...
2025-11-20 01:58
Earnings Outlook For Agios Pharmaceuticals
Agios Pharmaceuticals (NASDAQ:AGIO) is gearing up to announce its quarterly ear...
2025-10-30 03:02
Agios to Present at Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025
Agios Pharmaceuticals announces its management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025, at 8:40 a.m. ET. The presentation will be webcast live on the company's Investors website, with a replay available for two weeks. Agios is a leader in PK activation and develops therapies for rare diseases, including PK deficiency and other hematologic conditions.
2025-05-28 11:00
RBC Capital Reiterates Outperform on Agios Pharmaceuticals, Maintains $55 Price Target
RBC Capital analyst Gregory Renza reiterates Agios Pharmaceuticals (NASDAQ:AGIO) with a Outperform and maintains $55 price target.
2024-09-19 21:08
